Compile Data Set for Download or QSAR
Report error Found 150 Enz. Inhib. hit(s) with Target = 'Epidermal growth factor receptor [1-18,20-1210]'
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM112499(DACOMITINIB | US8623883, No. 2 | WO2022090481, Exa...)
Affinity DataIC50: 0.0100nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/21/2022
Entry Details
WIPO WO2022090481
PDB3D3D Structure (crystal)
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM50322823((S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahy...)
Affinity DataIC50: 0.0200nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/21/2022
Entry Details
WIPO WO2022090481
PDB3D3D Structure (crystal)
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538119(US11253516, Example 21)
Affinity DataIC50: 0.100nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700922(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6-methyl...)
Affinity DataIC50: 0.100nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538123(US11253516, Example 25)
Affinity DataIC50: 0.200nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538125(US11253516, Example 27)
Affinity DataIC50: 0.300nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538120(US11253516, Example 22)
Affinity DataIC50: 0.400nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM50029668(AZD-9291 | Osimertinib | US10085983, Compound AZD-...)
Affinity DataIC50: 0.5nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/21/2022
Entry Details
WIPO WO2022090481

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538117(US11253516, Example 19)
Affinity DataIC50: 0.700nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538108(US11253516, Example 10)
Affinity DataIC50: 0.700nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538126(US11253516, Example 28)
Affinity DataIC50: 0.900nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700935(N-(2,5-dichloropyrimidin-4-yl)-1- (methylsulfonyl)...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700934(N-(5-amino-2-((2- (dimethylamino)ethyl)(methyl) am...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700933(methyl 2-chloro-4-((1- (methylsulfonyl)-1,2,3,4- t...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700932(N-(5-amino-4-methoxy-2-(4-(4- methylpiperazin-1-yl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700796(N1-(2,5-dichloropyrimidin-4- yl)benzen-1,2-diamine...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700939(isopropyl 2-chloro-4-((1- (methylsulfonyl)indolin-...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700794(2,5-dichloro-N-(2- nitrophenyl)pyrimidin-4-amine |...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700938(methyl 2-chloro-4-((1- (methylsulfonyl)indolin-7- ...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700937(tert-butyl (2-((2-acrylamido-4-((5- chloro-4-((1- ...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700936(N-(2,5-dichloropyrimidin-4-yl)-1- (ethylsulfonyl)i...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700927(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-5-methyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700926(N-(6-((2,5-dichloropyrimidin-4- yl)amino)-2,3- dim...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700925(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6- ethyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700924(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6-ethylp...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700931(N-(5-amino-2-(4- (dimethylamino)piperidin-1-yl)-4-...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700930(tert-butyl (2-((2-acrylamido-4-((5- chloro-4-((1-(...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700929(N-(2,5-dichloropyrimidin-4-yl)-1- (methylsulfonyl)...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700928(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-5- methy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700887(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)benzen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700951(N-(5-amino-4-methoxy-2-(2- (piperidin-1- yl)ethoxy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700950(N-(5-amino-4-methoxy-2-(2- morpholinoethoxy)phenyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700885(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)pr...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700949(N-(5-amino-4-methoxy-2- (methyl(2-(4-methylpiperaz...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700884(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)et...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700948(2-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-1...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700891(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)ethane...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700954(N-(2,3-dimethyl-6-nitrophenyl)- N-methylacetamide ...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700889(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)propan...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700952(N-(5-amino-2-((2-(azetidin-1- yl)ethyl)(methyl)ami...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700943(N-(2-chloro-5- (trifluoromethyl)pyrimidin-4-yl)-1-...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700878(tert-butyl (4-((2- (dimethylamino)ethyl)(methyl) a...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700942(tert-butyl (5-acrylamido-2- methoxy-4-(methyl(2- m...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700865(tert-butyl (4-fluoro-2-methoxy-5- nitrophenyl)carb...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700941(N-(5-amino-2-(2- (dimethylamino)ethoxy)-4- methoxy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700843(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)pr...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700940(2-chloro-4-((1- (methylsulfonyl)indolin-7- yl)amin...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700883(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-4...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700947(2-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl) i...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700946(N-(6-((2,5-dichloropyrimidin-4- yl)amino)quinoxali...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

Displayed 1 to 50 (of 150 total ) | Next | Last >>
Jump to: